NR4A1 and breast carcinoma: Another large international retrospective cohort study that included 1236 breast cancer patients with germline BRCA1/2 mutations diagnosed at age ≤40 years examined clinical outcomes associated with each BRCA mutation type and hormone receptor (HR) status [224].